Alfacapital.com.cy

Alfacapital is ranked 3,776,483 in the United States. 'Home.'

3,776,483Rank in United States

10,781,382Worldwide Rank

Monthly pages viewed1,372
Monthly visits 484
Value per visitor--
Estimated worth$1,052.95
External links19
Number of pages--

Last Updated: 04/15/2018 . Estimated data, read disclaimer.

Visitors

Traffic History 90 Day Average
Worldwide Rank9,059,985 -3,087,028
Daily Visitors24+60%
Daily Visitors Rank8,021,389 -3,793,391
Daily Pageviews0+30%
Daily Pageviews Rank11,355,051 -1,868,028
Pageviews Per User1.10 -20%
Content

www.Alfacapital.com.cy

Topics: Mifid, To Become A Client, and Disclaimers.

26 users visit the site each day, each viewing 1.10 pages.

Server
Server Location
Spidernet Services Limited
Nicosia
Cyprus
35.17, 33.37

dns1.spidernet.net, dns2.spidernet.net, and dns0.spidernet.net are its DNS Nameservers. It is hosted by Spidernet Services Limited Nicosia, using Microsoft-IIS/6 web server. ASP.NET is its coding language environment.

IP: 194.154.128.99

Powered by: ASP.NET

Web Server: Microsoft-IIS/6

Encoding: utf-8

PING www. (194.154.128.99) 56(84) bytes of data.
64 bytes from durer.spidernet.net (194.154.128.99): icmp_req=1 ttl=117 166 ms
64 bytes from durer.spidernet.net (194.154.128.99): icmp_req=2 ttl=117 164 ms
64 bytes from durer.spidernet.net (194.154.128.99): icmp_req=3 ttl=117 163 ms
--- www. ping statistics ---
3 packets transmitted, 3 received, 0% packet loss, time 2002ms
rtt min/avg/max/mdev = 163.648/164.926/166.925/1.506 ms
rtt min/avg/max/mdev = 163.648/164.926/166.925/1.506 ms

A time of 166 ms, is recorded in a ping test.

Server Setup
Date:--
Server:Microsoft-IIS/6.0
X-Powered-By:ASP.NET
X-AspNet-Version:4.0.30319
Set-Cookie:--
Cache-Control:private
Content-Type:text/html; charset=utf-8
Content-Length:10671
Similar domains
  • alfacapital.com.ua Equity Research, Companies, Research Team

    alfacapital.com.ua

  • AlfaCapital Group

    alfacapitalgroup.net

  • alfacar.com

  • Alfacat

    alfacat.se

  • Tamir Biotechnology, Inc. (formerly Alfacell Corporation) targeting microRNAs, is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials.

    alfacell.com